Purchase this article with an account.
J. Ahn, J. Kim, J. Kim, Y. Yu, K. Park, D. Kim, K.-W. Kim; Anti-Recoverin Antibody Could Pass Through Blood-Retinal Barrier to Induce Cancer-Associated Retinopathy. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4753. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate whether anti-recoverin antibody passes through the blood-retinal barrier to induce cancer-associated retinopathy (CAR).
The fluorescein-tagged anti-recoverin antibody was intravenously injected via tail vein and the eye was enucleated after 8 hours, 24 hours and 48 hours. To disrupt the blood retinal barrier (BRB), vascular endothelial growth factor was injected into the intravitreal cavity and anti-recoverin antibody was intravenously injected 24 hours later. Immunohistochemistry for recoverin and TUNEL staining were performed.
The anti-recoverin antibody was identified in the inner, outer plexiform and outer nuclear layer 8 hours after the injection. With the disruption of BRB, the immunofluorescence was increased compared to the control without the disruption of BRB.
Our data suggests that the anti-recoverin antibody, as a cause of CAR, could penetrate into retinal layers from the blood flow, and in addition, increased vascular permeability may be one mechanism in which the anti-recoverin antibody passes through BRB to induce CAR.
This PDF is available to Subscribers Only